• María Pérez-Mato, Esteban López-Arias, Ana Bugallo-Casal, Clara Correa-Paz, Susana Arias, Manuel Rodríguez-Yáñez, María Santamaría-Cadavid, and Francisco Campos.
• Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
• Neuroscience. 2024 Jul 9; 550: 304230-42.

AbstractThe constant failure of new neuroprotective therapies for ischemic stroke has partially halted the search for new therapies in recent years, mainly because of the high investment risk required to develop a new treatment for a complex pathology, such as stroke, with a narrow intervention window and associated comorbidities. However, owing to recent progress in understanding the stroke pathophysiology, improvement in patient care in stroke units, development of new imaging techniques, search for new biomarkers for early diagnosis, and increasingly widespread use of mechanical recanalization therapies, new opportunities have opened for the study of neuroprotection. This review summarizes the main protective agents currently in use, some of which are already in the clinical evaluation phase. It also includes an analysis of how recanalization therapies, new imaging techniques, and biomarkers have improved their efficacy.Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…